A Caregiver's Story
Because caring for someone with cancer can be emotionally and physically challenging, it is possible for a caregiver -- who may be a spouse, son or daughter, friend or neighbor -- to become tired, rundown, or even depressed. Read a story about a caregiver who sought emotional support following the diagnosis of her husband's brain tumor.
An Interview with Maureen Zakowski
Pathologist Maureen Zakowski discusses her career at Memorial Sloan-Kettering and her own battle with endometrial cancer.
New Program for Women Faculty Affairs Is Making Strides
The representation of women on medical faculty is increasing from year to year, and this progress is particularly apparent at Memorial Sloan-Kettering Cancer Center, where the Women Faculty Affairs' Athena group seeks to provide women with mutual mentorship, support, and guidance.
Samuel and May Rudin Nursing Awards
Each year, the Samuel and May Rudin Nursing Awards recognize outstanding performance by Memorial Sloan-Kettering Cancer Center nursing staff. Award winners are nominated by their nursing peers, as well as by administrative and physician colleagues.
Adult Survivors of Childhood Cancer Face Health Issues
Almost three-fourths of pediatric cancer survivors will have a chronic health problem within 30 years after the cancer diagnosis, with 40 percent experiencing a serious, life-threatening, disabling, or fatal condition, according to investigators from Memorial Sloan-Kettering Cancer Center, St. Jude Children's Research Hospital, and other institutions.
New Clues About Blood Cell Production Pathway
Memorial Sloan-Kettering scientists led by cancer biologist Joan Massagué have discovered a new branch in the signaling network of a protein called transforming growth factor-beta (TGF-beta). The branch, described in the June 2 issue of Cell, is part of a larger TGF-beta signaling pathway known to control the production of mature red blood cells
Cancer Drug May Alter Bone Metabolism
Research by Memorial Sloan-Kettering investigators suggests that patients taking imatinib (Gleevec) to treat chronic myeloid leukemia (CML) or gastrointestinal stromal tumors (GIST) may experience changes in bone metabolism. The results, published May 11 in the New England Journal of Medicine, indicate that imatinib, in addition to inhibiting proteins responsible for CML and GIST, blocks a receptor important to bone synthesis and remodeling.
Living Beyond Cancer Calendar
A searchable listing of all the upcoming survivorship workshops, support groups, and events hosted by Memorial Sloan-Kettering.
